Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells

Molecular Pharmacology

Volumn 85, Issue 3, 2014, Pages 408-419

  Booth, Laurence ^a   Roberts, Jane L ^a   Cruickshanks, Nichola ^a   Conley, Adam ^a   Durrant, David E ^a   Das, Anindita ^a   Fisher, Paul B ^a   Kukreja, Rakesh C ^a   Grant, Steven ^a   Poklepovic, Andrew ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL LINE, TUMOR; CHECKPOINT KINASE 2; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GASTROINTESTINAL NEOPLASMS; HISTONES; HUMANS; LYMPHOMA, B-CELL; MICE; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHORYLATION; RATS; UROGENITAL NEOPLASMS;

EID: 84894055948     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.090043     Document Type: Article

References (54)

1. Amir M, Zhao E, Fontana L, Rosenberg H, Tanaka K, Gao G, and Czaja MJ (2013) Inhibition of hepatocyte autophagy increases tumor necrosis factor-dependent liver injury by promoting caspase-8 activation. Cell Death Differ 20:878-887.
2. Antoni L, Sodha N, Collins I, and Garrett MD (2007) CHK2 kinase: Cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 7:925-936.
3. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, and Burow ME et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 71:4955-4967.
4. Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58:488-520.
5. Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, and Dent P (2013) PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther 14:458-465.
6. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, and Ratliff TL (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:220-224.
7. Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD, and Chen ZS (2012) PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Sci 103:1531-1537.
8. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
9. Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, and Dent P (2012) Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Mol Pharmacol 82:1217-1229.
10. Das A, Salloum FN, Xi L, Rao YJ, and Kukreja RC (2009) ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236-H1243.
11. Das A, Xi L, and Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585.
12. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, and Dent P et al. (2010) Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA 107:18202-18207.
13. Das A, Ockaili R, Salloum F, and Kukreja RC (2004) Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 286:H1455-H1460.
14. Das A, Xi L, and Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955.
15. Duong HQ, Hong YB, Kim JS, Lee HS, Yi YW, Kim YJ, Wang A, Zhao W, Cho CH, and Seong YS et al. (2013) Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. J Cell Mol Med 17: 1261-1270.
16. Eggen T, Sager G, Berg T, Nergaard B, Moe BT, and Ørbo A (2012) Increased gene expression of the ABCC5 transporter without distinct changes in the expression of PDE5 in human cervical cancer cells during growth. Anticancer Res 32:3055-3061.
17. Fang Y, Han SI, Mitchell C, Gupta S, Studer E, Grant S, Hylemon PB, and Dent P (2004) Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology 40: 961-971.
18. Fisher PW, Salloum F, Das A, Hyder H, and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601-1610.
19. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, and Valerie K (2007) Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67: 1046-1053.
20. Grivas PD, Hussain M, Hafez K, Daignault-Newton S, Wood D, Lee CT, Weizer A, Montie JE, Hollenbeck B, and Montgomery JS et al. (2013) A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology 82: 111-117.
21. Hudson MA and Herr HW (1995) Carcinoma in situ of the bladder. J Urol 153: 564-572.
22. Jones LE, Jr, Ying L, Hofseth AB, Jelezcova E, Sobol RW, Ambs S, Harris CC, Espey MG, Hofseth LJ, and Wyatt MD (2009) Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. Carcinogenesis 30:2123-2129.
23. Kanjanawart S, Gaysonsiri D, Tangsucharit P, Vannaprasaht S, Phunikhom K, Kaewkamson T, Wattanachai N, and Tassaneeyakul W (2011) Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. Int J Clin Pharmacol Ther 49:525-530.
24. Karami-Tehrani F, Moeinifard M, Aghaei M, and Atri M (2012) Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res 43: 470-475.
25. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, and Reuter VE (1996) Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: Correlation to clinical outcome. J Clin Oncol 14:2646-2652.
26. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Jr, Sullivan J, and Sarosdy MF et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205-1209.
27. Lavin MF and Kozlov S (2007) ATM activation and DNA damage response. Cell Cycle 6:931-942.
28. Liedtke C, Bangen JM, Freimuth J, Beraza N, Lambertz D, Cubero FJ, Hatting M, Karlmark KR, Streetz KL, and Krombach GA et al. (2011) Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces nonapoptotic liver injury. Gastroenterology 141:2176-2187.
29. Lu X, Nannenga B, and Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19:1162-1174.
30. Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, and Norlén BJ; Swedish-Norwegian Bladder Cancer Study Group (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 161:1124-1127.
31. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, and Elledge SJ (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97:10389-10394.
32. Milligan PA, Marshall SF, and Karlsson MO (2002) A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 53 (Suppl 1):45S-52S.
33. Ockaili R, Salloum F, Hawkins J, and Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263-H1269.
34. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, and Liu X et al. (2008) Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 7:1648-1662.
35. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE, Jr, Klein-Szanto AJ, and Farnell DR et al. (2001) Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 61: 3961-3968.
36. Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, Daneshmand S, Skinner EC, and Skinner DG (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174:103-106.
37. Rivera E (2003) Liposomal anthracyclines in metastatic breast cancer: Clinical update. Oncologist 8 (Suppl 2):3-9.
38. Roos WP and Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440-450.
39. Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, and Grant S (2010) Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 285: 10064-10077.
40. Salloum F, Yin C, Xi L, and Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595-597.
41. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, and Prabhakar S et al. (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294:H1398-H1406.
42. Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, and Kukreja RC (2006) Vardenafil: A novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 40:405-411.
43. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet JL, Delic J, and Merle-Beral H (2003) Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101:265-269.
44. Scafoglio C, Smolka M, Zhou H, Perissi V, and Rosenfeld MG. (2013) The co-repressor SMRT delays DNA damage-induced caspase activation by repressing pro-apoptotic genes and modulating the dynamics of checkpoint kinase 2 activation. PLoS One 8: E59986.
45. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, and Erickson LC (2008) Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 324:95-102.
46. Singal PK, Li T, Kumar D, Danelisen I, and Iliskovic N (2000) Adriamycin-induced heart failure: Mechanism and modulation. Mol Cell Biochem 207:77-86.
47. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, and Cote RJ (1998) Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 160:645-659.
48. Stolz A, Ertych N, and Bastians H (2011) Tumor suppressor CHK2: Regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 17: 401-405.
49. Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, and Schmidt-Ullrichr RK (2005) Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J Biol Chem 280:14597-14604.
50. Thrasher JB and Crawford ED (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957-972.
51. Torti FM and Lum BL (1984) The biology and treatment of superficial bladder cancer. J Clin Oncol 2:505-531.
52. Witjes JA, Caris CT, Mungan NA, Debruyne FM, and Witjes WP (1998) Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 160:1668-1671, discussion 1671-1672.
53. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, and Lee R et al. (2008) Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14: 5385-5399.
54. Zhang X, Yan G, Ji J, Wu J, Sun X, Shen J, Jiang H, and Wang H (2012) PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem 113:2738-2743.